A Phase I, Open-Label Study to Assess the Pharmacokinetics and Relative Bioavailability of AZD4635 in Non-Smoking Healthy Male Subjects, With the Option to Assess Food Effect, pH Effect and Absolute Bioavailability
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs AZD 4635 (Primary) ; AZD 4635 (Primary) ; Lansoprazole
- Indications Cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms Rel Bio
- Sponsors AstraZeneca
- 10 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Feb 2019 Planned End Date changed from 4 Apr 2019 to 28 Mar 2019.
- 26 Feb 2019 Planned primary completion date changed from 4 Apr 2019 to 28 Mar 2019.